Phase 1 Open-Label Study to Determine the Safety and Tolerability of AVID200, a Transforming Growth Factor B Inhibitor, in Diffuse Cutaneous Systemic Sclerosis
This study is being done to learn more about the safety of the study drug, AVID200, and to find out more about the effects of different study drug doses in people with scleroderma. AVID200 is referred to as an investigational drug because it is in the early stages of development and has not been approved by the U.S. Food and Drug Administration, which means that it is not available to be prescribed or sold. The study drug is given intravenously (in the vein) over 1 hour. Study drug is given once every 2 weeks for a total of 3 doses.
- Study Identifier: 832173